Skip to main content

Lycia Therapeutics to Present at Jefferies Healthcare Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

SOUTH SAN FRANCISCO, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced that Aetna Wun Trombley, Ph.D., President and Chief Executive Officer of Lycia, will present a corporate overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 2:00 pm ET in New York.

The Lycia management team will also host one-on-one meetings with investors on Wednesday, June 7th.

About Lycia Therapeutics
Lycia Therapeutics is a biotechnology company using its proprietary lysosomal targeting chimeras (LYTACs) platform to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to-treat diseases, including immunological and inflammatory diseases. Headquartered in South San Francisco, Lycia was established in 2019 in collaboration with academic founder Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University and 2022 Nobel Laureate. For more information, please visit www.lyciatx.com.

Media Inquiries:
liz@melonecomm.com

Company Inquiries:
info@lyciatx.com


Primary Logo

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  227.99
-6.28 (-2.68%)
AAPL  281.64
-11.44 (-3.90%)
AMD  548.35
+28.61 (5.50%)
BAC  58.21
+0.48 (0.83%)
GOOG  337.35
-7.69 (-2.23%)
META  543.60
-14.07 (-2.52%)
MSFT  360.67
-4.79 (-1.31%)
NVDA  198.44
-0.56 (-0.28%)
ORCL  156.27
-1.26 (-0.80%)
TSLA  376.99
+1.46 (0.39%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.